2-methyl-3-(2-trimethylsilanyl-ethoxymethyl)-3H-imidazole-4-carbaldehyde | 219504-28-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-methyl-3-(2-trimethylsilanyl-ethoxymethyl)-3H-imidazole-4-carbaldehyde
• 英文别名: 2-Methyl-1-(2-(trimethylsilyl)ethoxymethyl)imidazole-5-carboxyaldehyde；2-methyl-3-(2-trimethylsilylethoxymethyl)imidazole-4-carbaldehyde
• CAS: 219504-28-6
• 化学式: C₁₁H₂₀N₂O₂Si
• 分子量: 240.377
• InChiKey: NGVKNFQTEANDMG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.32
• 重原子数：
  16
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  44.1
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-methyl-3-(2-trimethylsilanyl-ethoxymethyl)-3H-imidazole-4-carbaldehyde 、 乙醇 、 甲基甲基硫代甲砜 在 sodium hydride 、 盐酸 作用下， 以 四氢呋喃 为溶剂， 生成
  参考文献：
  名称：

  Synthesis and evaluation of novel 3,4,6-substituted 2-quinolones as FMS kinase inhibitors

  摘要：

  A series of 3,4,6-substituted 2-quinolones has been synthesized and evaluated as inhibitors of the kinase domain of macrophage colony-stimulating factor-1 receptor (FMS). The fully optimized compound, 4-(4-ethyl-phenyl)-3-(2-methyl-3H-imidazol-4yl)-2-quinolone-6-carbonitrile 21b, has an IC50 of 2.5 nM in an in vitro assay and 5.0 nM in a bone marrow-derived macrophage cellular assay. Inhibition of FMS signaling in vivo was also demonstrated in a mouse pharmacodynamic model. (c) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.01.088
• 作为产物：
  描述：

  2-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazole 、 N,N-二甲基甲酰胺 在 叔丁基锂 作用下， 以 四氢呋喃 为溶剂， 生成 2-methyl-3-(2-trimethylsilanyl-ethoxymethyl)-3H-imidazole-4-carbaldehyde
  参考文献：
  名称：

  Synthesis and evaluation of novel 3,4,6-substituted 2-quinolones as FMS kinase inhibitors

  摘要：

  A series of 3,4,6-substituted 2-quinolones has been synthesized and evaluated as inhibitors of the kinase domain of macrophage colony-stimulating factor-1 receptor (FMS). The fully optimized compound, 4-(4-ethyl-phenyl)-3-(2-methyl-3H-imidazol-4yl)-2-quinolone-6-carbonitrile 21b, has an IC50 of 2.5 nM in an in vitro assay and 5.0 nM in a bone marrow-derived macrophage cellular assay. Inhibition of FMS signaling in vivo was also demonstrated in a mouse pharmacodynamic model. (c) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.01.088

文献信息

• [EN] IMIDAZOL-4-YL-ETHYNYL-PYRIDINE DERIVATIVES<br/>[FR] DERIVES DE L'IMIDAZOL-4-YL-ETHYNYL-PYRIDINE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2004080998A1

  公开（公告）日：2004-09-23

  4-[1-Aryl-imidazol-4-ylethynyl]-2-alkyl-pyridine and 1-heteroaryl-imidazol-4-ylethynyl]-2-alkyl-pyridine derivatives and pharmaceutically acceptable salts thereof for the treatment or prevention of disorders mediated full or in part by metabotropic glutamate receptor 5, e.g. acute, traumatic and chronic degenerative processes of the nervous system, such as Alzheimer's disease, senile dementia, Parkinson's disease, Huntington's chorea, amyotrophic lateral sclerosis and multiple sclerosis, psychiatric diseases such as schizophrenia and anxiety, depression, pain and drug dependency.

  4-[1-芳基-咪唑-4-基乙炔基]-2-烷基吡啶和1-杂环芳基-咪唑-4-基乙炔基]-2-烷基吡啶衍生物及其药用可接受盐，用于治疗或预防由代谢型谷氨酸受体5完全或部分介导的疾病，例如神经系统的急性、创伤性和慢性退行性过程，如阿尔茨海默病、老年性痴呆、帕金森病、亨廷顿舞蹈症、肌萎缩侧索硬化和多发性硬化，精神疾病如精神分裂症和焦虑、抑郁、疼痛和药物依赖。
• [EN] PROTEIN KINASE INHIBITORS<br/>[FR] INHIBITEURS DE PROTÉINE KINASES
  申请人：PHARMASCIENCE INC

  公开号：WO2013177668A1

  公开（公告）日：2013-12-05

  The present invention relates to a novel family of inhibitors of protein kinases. In particular, the present invention relates to inhibitors of the members of the Tec and Src protein kinase families.

  本发明涉及一种新型的蛋白激酶抑制剂家族。具体而言，本发明涉及Tec和Src蛋白激酶家族成员的抑制剂。
• PROTEIN KINASE INHIBITORS
  申请人：Pharmascience, Inc.

  公开号：US20150191473A1

  公开（公告）日：2015-07-09

  The present invention relates to a novel family of inhibitors of protein kinases. In particular, the present invention relates to inhibitors of the members of the Tec and Src protein kinase families.

  本发明涉及一种新型的蛋白激酶抑制剂家族。具体而言，本发明涉及Tec和Src蛋白激酶家族成员的抑制剂。
• Imidazole derivatives
  申请人：Hoffmann-La Roche Inc.

  公开号：US07153874B2

  公开（公告）日：2006-12-26

  The present invention provides 4-[1-Aryl-imidazol-4-ylethynyl]-2-alkyl-pyridine and 1-heteroaryl-imidazol-4-ylethynyl]-2-alkyl-pyridine derivatives and pharmaceutically acceptable salts thereof for the treatment or prevention of disorders mediated in full or in part by metabotropic glutamate receptor 5. These disorders include, e.g. acute, traumatic and chronic degenerative processes of the nervous system, such as Alzheimer's disease, senile dementia, Parkinson's disease, Huntington's chorea, amyotrophic lateral sclerosis and multiple sclerosis, psychiatric diseases, such as schizophrenia and anxiety, depression, pain and drug dependency.

  本发明提供4-[1-芳基咪唑-4-基乙炔基]-2-烷基吡啶和1-杂环芳基咪唑-4-基乙炔基]-2-烷基吡啶衍生物及其药学上可接受的盐，用于治疗或预防由代谢型谷氨酸受体5完全或部分介导的疾病。这些疾病包括，例如神经系统的急性、创伤性和慢性退行性过程，如阿尔茨海默病、老年性痴呆症、帕金森病、亨廷顿舞蹈症、肌萎缩性侧索硬化和多发性硬化症，精神疾病，如精神分裂症和焦虑、抑郁、疼痛和药物依赖症。